Do analysts rate ABC or ONT?

Oxford Nanopore Technologies has a consensus target price of GBX 212.60, suggesting a potential upside of 87.48%. Given Oxford Nanopore Technologies' stronger consensus rating and higher probable upside, analysts plainly believe Oxford Nanopore Technologies is more favorable than Abcam. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abcam 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Oxford Nanopore Technologies 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80

Do analysts recommend SLN or ONT?

Oxford Nanopore Technologies has a consensus price target of GBX 212.60, indicating a potential upside of 87.48%. Given Oxford Nanopore Technologies' stronger consensus rating and higher probable upside, analysts plainly believe Oxford Nanopore Technologies is more favorable than Silence Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silence Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Oxford Nanopore Technologies 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80

Oxford Nanopore Technologies (ONT) Competitors

GBX 117 +3.60 (+3.17%)

As of 03:34 AM Eastern

Compare

ONT vs. ABC, GNS, ERGO, OXB, and SLN

Should you buy Oxford Nanopore Technologies stock or one of its competitors? MarketBeat compares Oxford Nanopore Technologies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Oxford Nanopore Technologies include Abcam (ABC), Genus (GNS), Ergomed (ERGO), Oxford Biomedica (OXB), and Silence Therapeutics (SLN). These companies are all part of the "biotechnology" industry.

How does Oxford Nanopore Technologies compare to Abcam?

Abcam (LON:ABC) and Oxford Nanopore Technologies (LON:ONT) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, earnings, profitability and analyst recommendations.

Abcam has higher revenue and earnings than Oxford Nanopore Technologies. Oxford Nanopore Technologies is trading at a lower price-to-earnings ratio than Abcam, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abcam	£350.40M	0.00	N/A	£0.06	N/A
Oxford Nanopore Technologies	£223.90M	4.94	-£175.21M	-£15.10	N/A

Abcam has a net margin of 0.00% compared to Oxford Nanopore Technologies' net margin of -64.85%. Abcam's return on equity of 0.00% beat Oxford Nanopore Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abcam	N/A	N/A	N/A
Oxford Nanopore Technologies	-64.85%	-29.43%	-14.42%

In the previous week, Oxford Nanopore Technologies had 1 more articles in the media than Abcam. MarketBeat recorded 1 mentions for Oxford Nanopore Technologies and 0 mentions for Abcam. Abcam's average media sentiment score of 0.00 equaled Oxford Nanopore Technologies'average media sentiment score.

Company	Overall Sentiment
Abcam	Neutral
Oxford Nanopore Technologies	Neutral

Oxford Nanopore Technologies has a consensus target price of GBX 212.60, suggesting a potential upside of 87.48%. Given Oxford Nanopore Technologies' stronger consensus rating and higher probable upside, analysts plainly believe Oxford Nanopore Technologies is more favorable than Abcam.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abcam	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Oxford Nanopore Technologies	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

16.4% of Oxford Nanopore Technologies shares are held by institutional investors. 2.5% of Oxford Nanopore Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Abcam and Oxford Nanopore Technologies tied by winning 6 of the 12 factors compared between the two stocks.

How does Oxford Nanopore Technologies compare to Genus?

Genus (LON:GNS) and Oxford Nanopore Technologies (LON:ONT) are related small-cap companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, profitability, dividends, media sentiment and analyst recommendations.

Genus presently has a consensus price target of GBX 3,216.67, suggesting a potential upside of 46.61%. Oxford Nanopore Technologies has a consensus price target of GBX 212.60, suggesting a potential upside of 87.48%. Given Oxford Nanopore Technologies' higher possible upside, analysts clearly believe Oxford Nanopore Technologies is more favorable than Genus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genus	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Oxford Nanopore Technologies	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Genus has a beta of 0.901, suggesting that its stock price is 10% less volatile than the broader market. Comparatively, Oxford Nanopore Technologies has a beta of 0.92, suggesting that its stock price is 8% less volatile than the broader market.

Genus has a net margin of 7.07% compared to Oxford Nanopore Technologies' net margin of -64.85%. Genus' return on equity of 9.70% beat Oxford Nanopore Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genus	7.07%	9.70%	3.31%
Oxford Nanopore Technologies	-64.85%	-29.43%	-14.42%

In the previous week, Oxford Nanopore Technologies had 1 more articles in the media than Genus. MarketBeat recorded 1 mentions for Oxford Nanopore Technologies and 0 mentions for Genus. Genus' average media sentiment score of 0.00 equaled Oxford Nanopore Technologies'average media sentiment score.

Company	Overall Sentiment
Genus	Neutral
Oxford Nanopore Technologies	Neutral

Genus has higher revenue and earnings than Oxford Nanopore Technologies. Oxford Nanopore Technologies is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genus	£672M	2.17	£7.87M	£71.00	30.90
Oxford Nanopore Technologies	£223.90M	4.94	-£175.21M	-£15.10	N/A

52.2% of Genus shares are held by institutional investors. Comparatively, 16.4% of Oxford Nanopore Technologies shares are held by institutional investors. 0.7% of Genus shares are held by insiders. Comparatively, 2.5% of Oxford Nanopore Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Genus beats Oxford Nanopore Technologies on 9 of the 15 factors compared between the two stocks.

How does Oxford Nanopore Technologies compare to Ergomed?

Oxford Nanopore Technologies (LON:ONT) and Ergomed (LON:ERGO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk.

16.4% of Oxford Nanopore Technologies shares are owned by institutional investors. Comparatively, 71.1% of Ergomed shares are owned by institutional investors. 2.5% of Oxford Nanopore Technologies shares are owned by company insiders. Comparatively, 18.2% of Ergomed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Oxford Nanopore Technologies currently has a consensus target price of GBX 212.60, suggesting a potential upside of 87.48%. Given Oxford Nanopore Technologies' stronger consensus rating and higher probable upside, analysts clearly believe Oxford Nanopore Technologies is more favorable than Ergomed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oxford Nanopore Technologies	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Ergomed	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Ergomed has lower revenue, but higher earnings than Oxford Nanopore Technologies. Oxford Nanopore Technologies is trading at a lower price-to-earnings ratio than Ergomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford Nanopore Technologies	£223.90M	4.94	-£175.21M	-£15.10	N/A
Ergomed	£152.09M	0.00	£15M	£0.29	N/A

Ergomed has a net margin of 9.87% compared to Oxford Nanopore Technologies' net margin of -64.85%. Ergomed's return on equity of 18.08% beat Oxford Nanopore Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oxford Nanopore Technologies	-64.85%	-29.43%	-14.42%
Ergomed	9.87%	18.08%	10.16%

In the previous week, Oxford Nanopore Technologies had 1 more articles in the media than Ergomed. MarketBeat recorded 1 mentions for Oxford Nanopore Technologies and 0 mentions for Ergomed. Oxford Nanopore Technologies' average media sentiment score of 0.00 equaled Ergomed'saverage media sentiment score.

Company	Overall Sentiment
Oxford Nanopore Technologies	Neutral
Ergomed	Neutral

Oxford Nanopore Technologies has a beta of 0.92, meaning that its share price is 8% less volatile than the broader market. Comparatively, Ergomed has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market.

Summary

Ergomed beats Oxford Nanopore Technologies on 8 of the 14 factors compared between the two stocks.

How does Oxford Nanopore Technologies compare to Oxford Biomedica?

Oxford Biomedica (LON:OXB) and Oxford Nanopore Technologies (LON:ONT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, earnings, institutional ownership, dividends, valuation and risk.

Oxford Biomedica has a net margin of -17.85% compared to Oxford Nanopore Technologies' net margin of -64.85%. Oxford Nanopore Technologies' return on equity of -29.43% beat Oxford Biomedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oxford Biomedica	-17.85%	-48.56%	-12.67%
Oxford Nanopore Technologies	-64.85%	-29.43%	-14.42%

32.4% of Oxford Biomedica shares are owned by institutional investors. Comparatively, 16.4% of Oxford Nanopore Technologies shares are owned by institutional investors. 34.8% of Oxford Biomedica shares are owned by company insiders. Comparatively, 2.5% of Oxford Nanopore Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Oxford Nanopore Technologies had 1 more articles in the media than Oxford Biomedica. MarketBeat recorded 1 mentions for Oxford Nanopore Technologies and 0 mentions for Oxford Biomedica. Oxford Biomedica's average media sentiment score of 0.00 equaled Oxford Nanopore Technologies'average media sentiment score.

Company	Overall Sentiment
Oxford Biomedica	Neutral
Oxford Nanopore Technologies	Neutral

Oxford Biomedica has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market. Comparatively, Oxford Nanopore Technologies has a beta of 0.92, suggesting that its share price is 8% less volatile than the broader market.

Oxford Biomedica presently has a consensus target price of GBX 669.85, indicating a potential upside of 19.62%. Oxford Nanopore Technologies has a consensus target price of GBX 212.60, indicating a potential upside of 87.48%. Given Oxford Nanopore Technologies' higher probable upside, analysts plainly believe Oxford Nanopore Technologies is more favorable than Oxford Biomedica.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oxford Biomedica	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Oxford Nanopore Technologies	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Oxford Biomedica has higher earnings, but lower revenue than Oxford Nanopore Technologies. Oxford Biomedica is trading at a lower price-to-earnings ratio than Oxford Nanopore Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford Biomedica	£168.74M	4.02	-£143.51M	-£26.92	N/A
Oxford Nanopore Technologies	£223.90M	4.94	-£175.21M	-£15.10	N/A

Summary

Oxford Biomedica beats Oxford Nanopore Technologies on 8 of the 15 factors compared between the two stocks.

How does Oxford Nanopore Technologies compare to Silence Therapeutics?

Silence Therapeutics (LON:SLN) and Oxford Nanopore Technologies (LON:ONT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, earnings, risk, analyst recommendations and media sentiment.

Silence Therapeutics has higher earnings, but lower revenue than Oxford Nanopore Technologies. Oxford Nanopore Technologies is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silence Therapeutics	£11.35M	0.00	N/A	-£48.60	N/A
Oxford Nanopore Technologies	£223.90M	4.94	-£175.21M	-£15.10	N/A

16.4% of Oxford Nanopore Technologies shares are held by institutional investors. 2.5% of Oxford Nanopore Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Silence Therapeutics has a net margin of 0.00% compared to Oxford Nanopore Technologies' net margin of -64.85%. Silence Therapeutics' return on equity of 0.00% beat Oxford Nanopore Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silence Therapeutics	N/A	N/A	N/A
Oxford Nanopore Technologies	-64.85%	-29.43%	-14.42%

In the previous week, Oxford Nanopore Technologies had 1 more articles in the media than Silence Therapeutics. MarketBeat recorded 1 mentions for Oxford Nanopore Technologies and 0 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 0.00 equaled Oxford Nanopore Technologies'average media sentiment score.

Company	Overall Sentiment
Silence Therapeutics	Neutral
Oxford Nanopore Technologies	Neutral

Oxford Nanopore Technologies has a consensus price target of GBX 212.60, indicating a potential upside of 87.48%. Given Oxford Nanopore Technologies' stronger consensus rating and higher probable upside, analysts plainly believe Oxford Nanopore Technologies is more favorable than Silence Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silence Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Oxford Nanopore Technologies	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Summary

Oxford Nanopore Technologies beats Silence Therapeutics on 9 of the 12 factors compared between the two stocks.

Get Oxford Nanopore Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ONT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ONT vs. The Competition

Export

Metric	Oxford Nanopore Technologies	Biotechnology Industry	Healthcare Sector	LON Exchange
Market Cap	£1.11B	£3.54B	£6.86B	£2.82B
Dividend Yield	N/A	3.78%	2.59%	6.15%
P/E Ratio	-7.51	7.38	282.27	368.29
Price / Sales	4.94	1,250.98	581.52	83,501.30
Price / Cash	4.04	44.80	28.60	27.89
Price / Book	1.69	16.78	10.93	7.04
Net Income	-£175.21M	-£12.56M	£3.49B	£5.89B
7 Day Performance	3.17%	-1.82%	-0.64%	6.05%
1 Month Performance	-5.81%	-8.45%	-3.78%	-0.22%
1 Year Performance	-43.16%	48.33%	61.99%	63.72%

Oxford Nanopore Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ONT Oxford Nanopore Technologies	2.5712 of 5 stars	GBX 117 +3.2%	GBX 212.60 +81.7%	-43.2%	£1.14B	£223.90M	N/A	1,281
ABC Abcam	N/A	N/A	N/A	N/A	£2.81B	£350.40M	20,433.33	1,650	Gap Up High Trading Volume
GNS Genus	3.3268 of 5 stars	GBX 2,206 -0.5%	GBX 3,216.67 +45.8%	-11.9%	£1.47B	£672M	31.07	480
ERGO Ergomed	N/A	N/A	N/A	N/A	£701.00M	£152.09M	4,641.38	6
OXB Oxford Biomedica	N/A	GBX 558.48 +0.4%	GBX 633.38 +13.4%	+20.6%	£675.97M	£168.74M	N/A	891	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:ONT) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oxford Nanopore Technologies (ONT) Competitors

ONT vs. ABC, GNS, ERGO, OXB, and SLN

How does Oxford Nanopore Technologies compare to Abcam?

Summary

How does Oxford Nanopore Technologies compare to Genus?

Summary

How does Oxford Nanopore Technologies compare to Ergomed?

Summary

How does Oxford Nanopore Technologies compare to Oxford Biomedica?

Summary

How does Oxford Nanopore Technologies compare to Silence Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONT vs. The Competition

Oxford Nanopore Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oxford Nanopore Technologies (ONT) Competitors

ONT vs. ABC, GNS, ERGO, OXB, and SLN

How does Oxford Nanopore Technologies compare to Abcam?

Which has higher valuation and earnings, ABC or ONT?

Is ABC or ONT more profitable?

Does the media prefer ABC or ONT?

Do analysts rate ABC or ONT?

Do insiders & institutionals believe in ABC or ONT?

Summary

How does Oxford Nanopore Technologies compare to Genus?

Do analysts rate GNS or ONT?

Which has more volatility & risk, GNS or ONT?

Is GNS or ONT more profitable?

Does the media favor GNS or ONT?

Which has preferable earnings & valuation, GNS or ONT?

Do insiders and institutionals believe in GNS or ONT?

Summary

How does Oxford Nanopore Technologies compare to Ergomed?

Do insiders & institutionals hold more shares of ONT or ERGO?

Do analysts prefer ONT or ERGO?

Which has stronger valuation and earnings, ONT or ERGO?

Is ONT or ERGO more profitable?

Does the media prefer ONT or ERGO?

Which has more risk & volatility, ONT or ERGO?

Summary

How does Oxford Nanopore Technologies compare to Oxford Biomedica?

Is OXB or ONT more profitable?

Do insiders and institutionals have more ownership in OXB or ONT?

Does the media favor OXB or ONT?

Which has more risk & volatility, OXB or ONT?

Do analysts recommend OXB or ONT?

Which has higher valuation & earnings, OXB or ONT?

Summary

How does Oxford Nanopore Technologies compare to Silence Therapeutics?

Which has stronger valuation & earnings, SLN or ONT?

Do insiders & institutionals believe in SLN or ONT?

Is SLN or ONT more profitable?

Does the media favor SLN or ONT?

Do analysts recommend SLN or ONT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONT vs. The Competition

Oxford Nanopore Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools